Companion Animal Osteoarthritis Market Size, Share & Trends Analysis Report By Product (Biologics, Pharmaceuticals, Nutritional Supplements), By Animal (Canine), By Route Of Administration, Distribution Channel, By Region, And Segment Forecasts, 2026 - 20

Companion Animal Osteoarthritis Market Summary

The global companion animal osteoarthritis market size was estimated at USD 2.98 billion in 2025 and is projected to reach USD 5.22 billion by 2033, growing at a CAGR of 6.46% from 2026 to 2033. The key market growth drivers include advancements in pet treatment, the increasing humanization of pets & expenditure on pets, support programs & initiatives, and changing pet demographics globally.

Advancements in osteoarthritis (OA) treatment for companion animals (CA) are transforming the landscape of veterinary care. With ongoing advancements in veterinary medicine, new therapies and treatment methods for osteoarthritis are becoming increasingly targeted and effective, thereby enhancing the overall management of the condition and improving the quality of life for affected pets.

The development of more effective medications, biologics, and non-pharmaceutical interventions is playing a significant role in this evolution. For example, in recent years, there has been a growing interest in regenerative medicine, including stem cell therapy and platelet-rich plasma (PRP), which have shown promising results in reducing inflammation and promoting healing in joints affected by osteoarthritis. These treatments have become increasingly accessible in veterinary practices, providing pet owners with more options for effective solutions for their pets. According to the American Veterinary Medical Association (AVMA) article in February 2024, advancements in regenerative medicine have significantly improved the treatment of joint conditions like osteoarthritis, helping pets manage pain and improve mobility. Additionally, the rise in precision medicine-where treatments are tailored to the specific needs of individual pets is helping optimize osteoarthritis management.

This approach enables more accurate diagnoses and the administration of therapies that specifically target the underlying causes of osteoarthritis, rather than merely alleviating symptoms. As the veterinary industry continues to evolve toward more specialized and individualized care, these advancements will likely continue to improve outcomes for pets with osteoarthritis. The U.S. Food and Drug Administration (FDA) approved Librela (bedinvetmab) for the control of pain associated with osteoarthritis in dogs on May 5, 2023. This approval marked a significant advancement in veterinary pain management, as Librela became the first and only once-monthly, anti-nerve growth factor (NGF) monoclonal antibody treatment for canine osteoarthritis pain in the United States. Furthermore, the approval of innovative veterinary drugs and treatment modalities plays a crucial role in advancing the osteoarthritis care for companion animals. Similar to the trend in other segments of animal health, regulatory bodies such as the U.S. FDA are approving more treatments aimed at improving joint health

The growing focus on innovation in the treatment of osteoarthritis, supported by rising veterinary care expenditures and increasing pet health awareness, is driving demand for advanced solutions. Pet owners are increasingly willing to invest in advanced treatments that enhance their pets' quality of life, driving greater market growth in osteoarthritis care. A survey by Talker Research for MetLife found that in 2024, the average pet parent spent USD 2,085.60 on their pets. Despite rising inflation, 36% of respondents anticipated spending even more in 2025, indicating a growing willingness to invest in pet health.

These ongoing advancements, combined with the growing adoption of pet insurance and increasing focus on animal health, are expected to further fuel demand for innovative osteoarthritis treatments. As the field of veterinary health evolves and new technologies emerge, the ability to better manage osteoarthritis in companion animals will continue to improve, driving further expansion of this specialized market.

Global Companion Animal Osteoarthritis Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the companion animal osteoarthritis market report based on product, animal, route of administration, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biologics
• Stem Cells
• Platelet-Rich Plasma (PRP)
• Monoclonal Antibodies (mAb)
• Other Biologics
• Viscosupplements
• Pharmaceuticals
• Steroids
• NSAIDS
• Others
• Nutritional Supplements
• Chondroitin
• Glucosamine
• Methylsulfonylmethane (MSM)
• Hyaluronic Acid (HA)
• Omega-3 Fatty Acids
• Others
• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Canine
• Equine
• Feline
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Injectable
• Intra-muscular
• Intra-articular
• Other Injectable
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals/Clinics
• E-commerce
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• India
• China
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more